Table 2. Objective Response Rate, Progression-Free, and Overall Survival to PD-1/PD-L1 Blockade in High and Low TMB Non–Small Cell Lung Cancer According to PD-L1 Expression Subgroups.
Outcome and PD-L1 tumor proportion score | Low TMB | High TMB | P value |
---|---|---|---|
Objective response rate, % (95% CI) | |||
<1% | 8.7 (5.5-12.9) | 46.7 (28.3-65.7) | <.001 |
1%-49% | 18.7 (14.1-23.9) | 50.0 (31.3-68.7) | <.001 |
≥50% | 38.1 (33.3-43.0) | 56.5 (41.1-71.1) | .02 |
Progression-free survival, median (95% CI), mo | |||
<1% | 2.1 (2.0-2.4) | 10.7 (8.2-24.4) | <.001 |
1%-49% | 2.9 (2.5-3.6) | 13.6 (8.6-NR) | <.001 |
≥50% | 5.2 (4.6-6.2) | 18.1 (8.6-NR) | <.001 |
Overall survival, median (95% CI), mo | |||
<1% | 10.4 (7.9-13.6) | 23.9 (16.7-NR) | .07 |
1%-49% | 11.3 (9.6-14.7) | NR (21.2-NR) | <.001 |
≥50% | 21.4 (17.5-25.9) | 47.7 (35.4-NR) | .02 |
Abbreviations: NR, not reached; PD-1, programmed cell death–1; PD-L1, programmed death ligand–1; TMB, tumor mutation burden.